ClinicalTrials.gg

Program

DA-302168S

A development code. Also written as “[14C] DA-302168S” and “15 mg DA-302168S tablet”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2, led by Chendu DIAO Pharmaceutical Group.

Furthest: phase 3, since May 27, 20269 company-led studies, 5 open or runningNext primary completion: Dec 12, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chendu DIAO Pharmaceutical Group95 open or runningphase 3since May 27, 2026Jul 26, 2024Dec 12, 2026phase 1 · NCT07938515

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 26, 2024First studies: 2 phase 1 studies in OverweightFirst studyNCT06534346, NCT06534320
  2. Aug 1, 2024Phase 1 study in OverweightNCT06541730 · 48 enrolled · China
  3. Apr 11, 2025Phase 2 study in OverweightNCT06953063 · 250 enrolled · China
  4. May 27, 2026Phase 3 study in OverweightPhase 3 reachedNCT07629544 · 840 planned · China
  5. Aug 5, 2026Phase 2 study in Diabetes Mellitus, Type 2NCT07755150 · 272 planned · China
  6. Sep 29, 2026Phase 1 study in Healthy Adult SubjectsNCT07857265 · 10 planned
  7. Oct 9, 2026Phase 1 study in ObesityNCT07877038 · 32 planned
  8. Nov 10, 2026Phase 1 study in ObesityNCT07938515 · 32 planned · China

Ahead

  1. Dec 12, 2026Primary completion: phase 1 study in ObesityNCT07938515
  2. Dec 20, 2026Primary completion: phase 1 study in Healthy Adult SubjectsNCT07857265
  3. Apr 7, 2027Primary completion: phase 1 study in ObesityNCT07877038
  4. Jul 9, 2027Primary completion: phase 3 study in OverweightNCT07629544

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07938515Obesity · China1RecruitingDec 12, 202632
NCT07877038Obesity1Not yet recruitingApr 7, 202732
NCT07857265Healthy Adult Subjects1Not yet recruitingDec 20, 202610
NCT07755150Diabetes Mellitus, Type 2 · China2Not yet recruitingOct 20, 2027272
NCT07629544Overweight · China3RecruitingJul 9, 2027840
NCT06953063Overweight · China2CompletedDec 15, 2025250
NCT06541730Overweight · China1CompletedJan 30, 202548
NCT06534346Overweight · China1CompletedAug 3, 202416
NCT06534320Overweight · China1CompletedDec 31, 202450

How it is read

Names in the registry

  • “DA-302168S”, 9 entries
  • “[14C] DA-302168S”, 1 entry
  • “15 mg DA-302168S tablet”, 1 entry

Codes read as this program: DA302168S.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.